Detalhe da pesquisa
1.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-36001711
2.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 29(14): 1795-1807, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37905526
3.
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Mult Scler
; 27(3): 420-429, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32351164
4.
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler
; 26(13): 1719-1728, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31675266
5.
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Mult Scler
; 25(12): 1605-1617, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30289355
6.
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
CNS Drugs
; 37(5): 441-452, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37155132
7.
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
Mult Scler Relat Disord
; 57: 103350, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-35158459
8.
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
Mult Scler J Exp Transl Clin
; 8(4): 20552173221135888, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36407472
9.
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Adv Ther
; 39(4): 1810-1831, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35211872
10.
Patients' Experiences in Transitioning to Secondary Progressive Multiple Sclerosis: Qualitative Interviews.
Neurol Ther
; 10(2): 887-904, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-34392498
11.
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
Ther Adv Neurol Disord
; 14: 1756286421993999, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33796143
12.
B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
J Neuroimmunol
; 359: 577676, 2021 10 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34364105
13.
Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
Mult Scler J Exp Transl Clin
; 5(1): 2055217318822148, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30729026
14.
B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.
J Neuroimmunol
; 332: 187-197, 2019 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31077854
15.
Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
Expert Opin Drug Deliv
; 15(2): 127-135, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29206056
16.
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
Patient Prefer Adherence
; 12: 1289-1297, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30050291
17.
Subcutaneous peginterferon ß-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.
Neurodegener Dis Manag
; 7(1): 39-47, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28071330
18.
The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction.
Patient Prefer Adherence
; 11: 33-45, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28053511
19.
Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
Expert Opin Drug Deliv
; 8(12): 1543-53, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22032264